Allergan sees no need for big M&A deals as sales fall

Allergan isn’t looking at any large deals, chief executive officer Brent Sanders said, after the drugmaker posted second-quarter sales that fell short of analysts’ estimates.

Revenue at Allergan, which ended its $160bn (€144.25bn) planned merger with Pfizer in April, which was driven by Irish tax considerations, rose 1.5% to $3.68bn last quarter.

That was shy of the $3.72bn average of estimates from analysts.